| Literature DB >> 35795377 |
Offir Ukashi1, Barak Pflantzer2, Yiftach Barash3, Eyal Klang3, Shlomo Segev3, Doron Yablecovitch4, Uri Kopylov4, Shomron Ben-Horin4, Ido Laish4.
Abstract
Background: Screening with colonoscopy for all average-risk population is probably not cost-effective due to the limited sources and over-generalization of the risk, and risk stratification can be used to optimize colorectal cancer screening.Entities:
Keywords: advanced adenoma; advanced neoplasia; classification tree algorithm; colorectal cancer; screening colonoscopy
Year: 2022 PMID: 35795377 PMCID: PMC9252006 DOI: 10.1177/17562848221101291
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.802
Figure 1.Study flowchart.
Patient’s baseline characteristics.
| Demographics | |
| Age (years) median (IQR) | 55 (51–60) |
| Age group | |
| <50, | 899 (23.3%) |
| 50–59, | 1846 (47.9%) |
| 60–69, | 910 (23.6%) |
| ⩾70, | 201 (5.2%) |
| Sex | |
| Female, | 1032 (26.8%) |
| Male, | 2824 (73.2%) |
| Physical parameters | |
| Body mass index (kg/m2), mean (standard deviation)
| 26.48(±3.78) |
| Body mass index group (kg/m2)
| |
| <20, | 78 (2.3%) |
| 20–25, | 1169 (34%) |
| >25, | 2193 (63.7%) |
| Habits | |
| Current smoking, | 1404 (36.4%) |
| Alcohol use, | 22 (0.6%) |
| Exercise, | 2589 (74.4%) |
| Comorbidities | |
| Ischemic heart disease, | 181 (4.7%) |
| Hypertension, | 721 (18.7%) |
| Congestive heart failure, | 1 (<1%) |
| Diabetes, | 325 (8.4%) |
| Medications | |
| Amino salicylic acid, | 191 (5%) |
| Statins, | 321 (8.3%) |
| Hormone replacement therapy | 34 (<1%) |
IQR, interquartile range.
Data were missing for ⩽10%.
Colonoscopic findings.
| Normal colonoscopy, | 3240 (84%) |
| Non-advanced adenoma, | 471 (12.2%) |
| Location | |
| Proximal, | 190 (4.9%) |
| Distal, | 223 (5.8%) |
| Proximal and distal, | 58 (1.5%) |
| 1–2 non-advanced adenoma, | 429 (11.1%) |
| ⩾3 non-advanced adenoma, | 42 (1.1%) |
| Serrated adenoma, | 16 (0.4%) |
| Location | |
| Proximal, | 6 (0.2%) |
| Distal, | 10 (0.4%) |
| 1–2 serrated adenoma, | 14 (0.4%) |
| ⩾3 serrated adenoma, | 2 (0.1%) |
| Advanced adenoma, | 122 (3.2%) |
| Location | |
| Proximal, | 42 (1.1%) |
| Distal, | 76 (2%) |
| Proximal and distal, | 4 (0.1%) |
| Polyp characteristics | |
| Size ⩾ 1 cm, | 79 (2%) |
| Villous histology, | 73 (1.9%) |
| High-grade dysplasia, | 17 (0.4%) |
| Colon adenocarcinoma, | 7 (0.2%) |
| Staging | |
| Stage 1 ( | 2 |
| Stage 2 ( | 3 |
| Stage 3 ( | 2 |
| Stage 4 ( | - |
IQR, interquartile range.
Univariable and multivariable analyses for advanced neoplasia (AN).
| Patients with AN | Patients without AN | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|
| AOR (95% CI) | |||||
| Demographics | |||||
| Age (years), median (IQR) | 57 (52–62) | 54 (51–60) | 0.001 | 1.04 (1.01–1.06) | 0.003 |
| Age group, | |||||
| <0 | 19 (15%) | 880 (23.5%) | |||
| 50–59 | 62 (48%) | 1784 (48%) | 0.073 | ||
| 60–69 | 38 (29.5%) | 872 (23.5%) | 0.014 | ||
| ⩾70 | 10 (7.5%) | 191 (5%) | 0.026 | ||
| Sex | |||||
| Male, | 114 (88.4%) | 2710 (72.7%) | <0.001 | 2.69 (1.56–4.64) | <0.001 |
| Physical parameters | |||||
| Body mass index (kg/m2) mean (standard deviation)
| 27.10 (±3.70) | 26.46 (±3.78) | 0.077 | ||
| Body mass index group (kg/m2)
| |||||
| <20, | 1 (<1%) | 77 (2.1%) | |||
| 20–25, | 27 (20.9%) | 1142 (30.6%) | 0.559 | ||
| >25, | 88 (68.2%) | 2105 (56.4%) | 0.248 | ||
| Habits | |||||
| Smoking, | 69 (53.5%) | 1335 (35.8%) | <0.001 | 1.97 (1.38–2.81) | <0.001 |
| Alcohol use, | 1 (<1%) | 21 (<1%) | 0.754 | ||
| Exercise, | 79 (68.1%) | 2510 (74.6%) | 0.117 | ||
| Comorbidities | |||||
| Ischemic heart disease, | 12 (9.3%) | 169 (4.5%) | 0.012 | ||
| Hypertension, | 29 (22.5%) | 692 (18.6%) | 0.262 | ||
| Congestive heart failure, | 0 (0%) | 1 (<1%) | 0.853 | ||
| Diabetes, | 12 (9.3%) | 313 (8.4%) | 0.716 | ||
| Medications | |||||
| Amino salicylic acid, | 7 (5.4%) | 184 (4.9%) | 0.801 | ||
| Statins, | 1 (<1%) | 33 (<1%) | 0.464 | ||
| Hormone replacement therapy, | 13 (10%) | 308 (8.3%) | 0.895 | ||
AOR, adjusted odds ratio; CI, confidence interval; IQR, interquartile range.
Data were missing for ⩽10%.
Figure 2.Advanced neoplasia rate amomg the cohort population, devided to sex, smoking status, aspirin use, age groups (years), and BMI (body mass index) groups (kg/m2).
Figure 3.Classification tree algorithm for advanced neoplasia detection among average-risk population.